Risk evaluation and monitoring in multiple sclerosis therapeutics

BACKGROUND: Risk for multiple sclerosis (MS) disease-modifying therapies (DMT) must be assessed on an ongoing basis. Early concerns regarding the first-approved DMTs for MS have been mitigated, but recently licensed therapies have been linked to possibly greater risks. OBJECTIVES: The objective of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Clanet, Michel C, Wolinsky, Jerry S, Ashton, Raymond J, Hartung, Hans-Peter, Reingold, Stephen C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2014
Materias:
Meeting Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232326/
https://www.ncbi.nlm.nih.gov/pubmed/24293456
http://dx.doi.org/10.1177/1352458513513207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232326/
https://www.ncbi.nlm.nih.gov/pubmed/24293456
http://dx.doi.org/10.1177/1352458513513207

Ejemplares similares